Work

Abstract 851: AdAPT-001 demonstrates potent oncolytic activity, high levels of TGFβ inhibition, and encouraging clinical activity in refractory sarcoma: update of the BETA-PRIME trial and preclinical correlates

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-851

Authors: Chris Larson, Ana Sanchez, Farah Hedjran, Garett Soapes, Bryan Oronsky, Anthony P. Conley, Meaghan Stirn, Tony Reid

Institutions: EpicentRx, Inc. (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409690686

Cites:

Cited by:

Related to: 10